Infertility

Femovate Announces 30 New Early-Stage Femtech Startups for Its 2024 UX Design Sponsorship Program

Retrieved on: 
Wednesday, December 13, 2023

AUSTIN, Texas, Dec. 13, 2023 /PRNewswire-PRWeb/ -- Guidea, an award-winning, women-led UX design agency, today announced 30 new early-stage femtech companies for its 2024 UX design sponsorship program, Femovate, selected from 130 applications across six continents. Launched by Guidea in 2022, the Femovate program has invested more than $1 million in femtech innovation through its UX design sponsorship program, and elevates promising femtech startups by giving them the same kind of services that Guidea provides to the top Fortune 100 companies.

Key Points: 
  • Launched in 2022 by Guidea, an award-winning UX design agency, Femovate helps femtech startups overcome funding inequalities, along with massive scientific and clinical data gaps through its $1 million femtech innovation sponsorship program
    AUSTIN, Texas, Dec. 13, 2023 /PRNewswire-PRWeb/ -- Guidea , an award-winning, women-led UX design agency, today announced 30 new early-stage femtech companies for its 2024 UX design sponsorship program, Femovate , selected from 130 applications across six continents.
  • Launched by Guidea in 2022, the Femovate program has invested more than $1 million in femtech innovation through its UX design sponsorship program, and elevates promising femtech startups by giving them the same kind of services that Guidea provides to the top Fortune 100 companies.
  • The 30 companies selected for the 2024 Femovate program include:
    Deeplook Medical : Revolutionizing radiology for cancer screening, diagnosis, and treatment, with their FDA-approved, patent-protected software.
  • "I'm impressed with the caliber of the femtech companies I've been part of selecting for the 2024 Femovate cohort and the practical support they receive from Femovate."

Maya Barsky, MD, MSCI Joins the Center for Advanced Reproductive Services as a Lead Physician

Retrieved on: 
Tuesday, December 12, 2023

FARMINGTON, Conn., Dec. 12, 2023 /PRNewswire/ -- The Center for Advanced Reproductive Services, one of the leading family building programs in the country, announced Dr. Maya Barsky, reproductive endocrinologist, has joined as Lead Physician and Assistant Professor in the Department of Ob/Gyn at UConn School of Medicine.

Key Points: 
  • FARMINGTON, Conn., Dec. 12, 2023 /PRNewswire/ -- The Center for Advanced Reproductive Services, one of the leading family building programs in the country, announced Dr. Maya Barsky, reproductive endocrinologist, has joined as Lead Physician and Assistant Professor in the Department of Ob/Gyn at UConn School of Medicine.
  • "I am very fortunate to be a part of such a respected and successful program as the Center for Advanced Reproductive Services."
  • Dr. Barsky is available to connect with patients via telehealth appointments effective immediately, with in-person appointments beginning in January 2024.
  • Prior to joining The Center for Advanced Reproductive Services, she was part of a private fertility practice in Austin, TX for several years.

MOSIE BABY BECOMES THE FIRST COMPANY TO RECEIVE FDA CLEARANCE FOR AT-HOME INTRAVAGINAL INSEMINATION

Retrieved on: 
Wednesday, December 6, 2023

AUSTIN, Texas, Dec. 6, 2023 /PRNewswire/ -- Mosie Baby , a pioneering at-home fertility care company, has secured FDA Class II clearance for its Mosie Baby Kit making it the first and only FDA-cleared over-the-counter kit for use in intravaginal insemination (IVI).

Key Points: 
  • AUSTIN, Texas, Dec. 6, 2023 /PRNewswire/ -- Mosie Baby , a pioneering at-home fertility care company, has secured FDA Class II clearance for its Mosie Baby Kit making it the first and only FDA-cleared over-the-counter kit for use in intravaginal insemination (IVI).
  • Following its FDA 510k Class II clearance, Mosie Baby looks forward to expanding access to its Mosie Baby Kit which was determined to be "substantially equivalent" to a predicate device used in clinically administered intrauterine insemination (IUI).
  • As part of Mosie Baby's FDA Class II clearance, the Mosie Baby Kit was put through rigorous clinical and technical testing, including Human Sperm Survival Assay, vaginal irritation testing, and biocompatibility testing.
  • "The recent Mosie Baby clearance means hundreds of thousands of underserved people now benefit from an at home option.

Metabolon Wins National Institute of Health (NIH) Award to Develop Test to Improve Polycystic Ovary Syndrome (PCOS) Diagnostic Accuracy

Retrieved on: 
Tuesday, December 5, 2023

MORRISVILLE, N.C., Dec. 5, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced receipt of a National Institute of Health (NIH) award to improve the accuracy by which polycystic ovary syndrome (PCOS) can be diagnosed.

Key Points: 
  • PCOS is the most common cause of infertility worldwide, affecting an estimated 8-13% of women of childbearing age.
  • Current diagnoses typically require pelvic exams and blood tests to obtain a hormone profile, glucose tolerance, and lipid measurements.
  • This diagnostic algorithm likely misclassifies or outright misses a lot of cases," said Adam Kennedy, Associate Director of Research and Development at Metabolon.
  • "Metabolon's work in this area will potentially bring PCOS diagnostic guidelines into the 21st century using highly advanced, cutting-edge metabolomics science."

Amir Mor, Ph.D., M.D., Joins Fertility Centers of New England

Retrieved on: 
Tuesday, December 5, 2023

READING, Mass., Dec. 5, 2023 /PRNewswire/ -- The Fertility Centers of New England is pleased to welcome Amir Mor, Ph.D., M.D., as its newest infertility specialist.

Key Points: 
  • READING, Mass., Dec. 5, 2023 /PRNewswire/ -- The Fertility Centers of New England is pleased to welcome Amir Mor, Ph.D., M.D., as its newest infertility specialist.
  • Dr. Mor is board-certified in Obstetrics and Gynecology, and board-eligible in Reproductive Endocrinology and Infertility.
  • Dr. Mor joins Fertility Centers of New England from New York City where he was the founder and director of the Mor Fertility Center.
  • "Dr. Mor's dedication to patient care is well known in the New York City area, and we are delighted to have him join our team," said Fertility Centers of New England President Joseph A. Hill, M.D.

Majority of Canadian employers still not offering fertility benefits

Retrieved on: 
Monday, November 20, 2023

TORONTO, Nov. 20, 2023 /CNW/ - A new study of almost 1,000 Canadian employers finds most (53%) do not offer fertility benefits for employees.

Key Points: 
  • TORONTO, Nov. 20, 2023 /CNW/ - A new study of almost 1,000 Canadian employers finds most (53%) do not offer fertility benefits for employees.
  • Fertility benefits are essential because infertility affects approximately 1 in 6 Canadian couples and it comes with a heavy financial burden, leaving treatment out of reach for many.
  • Of the employers (47%) that do offer fertility benefits, less than 2% cover both drugs and treatment costs such as IVF procedures, sperm, eggs, and testing.
  • Tara notes some of the improvements include: of the employers offering benefits, 22% had no maximums on fertility drugs and other employers have increased their lifetime limits with almost a quarter offering at least $20,000 for fertility drugs.

The Institute of Human Genetics, Polish Academy of Sciences (IHG PAS) is Live on SOPHiA GENETICS

Retrieved on: 
Friday, November 17, 2023

BOSTON and ROLLE, Switzerland, Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading center for genetics research in Poland, is now live on the SOPHiA DDM™ Platform. IHG PAS will use SOPHiA GENETICS to advance its research into rare disorders, in particular male fertility.

Key Points: 
  • BOSTON and ROLLE, Switzerland, Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading center for genetics research in Poland, is now live on the SOPHiA DDM™ Platform.
  • IHG PAS will use SOPHiA GENETICS to advance its research into rare disorders, in particular male fertility.
  • Using the SOPHiA DDM™ Platform, IHG PAS will have analyzed results and streamlined insights in an efficient timeframe.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

The Institute of Human Genetics, Polish Academy of Sciences (IHG PAS) is Live on SOPHiA GENETICS

Retrieved on: 
Friday, November 17, 2023

BOSTON and ROLLE, Switzerland, Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading center for genetics research in Poland, is now live on the SOPHiA DDM™ Platform. IHG PAS will use SOPHiA GENETICS to advance its research into rare disorders, in particular male fertility.

Key Points: 
  • BOSTON and ROLLE, Switzerland, Nov. 17, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading center for genetics research in Poland, is now live on the SOPHiA DDM™ Platform.
  • IHG PAS will use SOPHiA GENETICS to advance its research into rare disorders, in particular male fertility.
  • Using the SOPHiA DDM™ Platform, IHG PAS will have analyzed results and streamlined insights in an efficient timeframe.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

Femometer Smart Ring Provides a Better Solution for Female Fertility

Retrieved on: 
Friday, November 17, 2023

On August 25, 2023, Femometer unveiled its new generation ovulation tracking device- Femometer Smart Ring.

Key Points: 
  • On August 25, 2023, Femometer unveiled its new generation ovulation tracking device- Femometer Smart Ring.
  • The Femometer Smart Ring is set to redefine the landscape of female health management.
  • The Femometer Smart Ring, in tandem with the Femometer App, leverages data-driven fertility tracking and personalized insights to help users optimize their fertility journey.
  • The Femometer Smart Ring is a direct response to the demand for advanced fertility tracking tools," said Zahara Miller, Chief Product Officer of Femometer.

Lupus Foundation of America Awards Four Grants to Support and Advance Childhood Lupus Research

Retrieved on: 
Wednesday, November 15, 2023

WASHINGTON, Nov. 15, 2023 /PRNewswire/ -- The Lupus Foundation of America (LFA) is pleased to announce four recipients of pediatric lupus research grants under the Michael Jon Barlin Pediatric Lupus Research Program.

Key Points: 
  • WASHINGTON, Nov. 15, 2023 /PRNewswire/ -- The Lupus Foundation of America (LFA) is pleased to announce four recipients of pediatric lupus research grants under the Michael Jon Barlin Pediatric Lupus Research Program.
  • The grants will support researchers in their studies of lupus in children as they address the most urgent challenges in this area of medicine.
  • Established in 2006 with the generous support of the Wallace H. Coulter Foundation, the LFA's Michael Jon Barlin Pediatric Lupus Research Program is the first and only national childhood lupus research program, founded in memory of Michael Jon Barlin who passed away at the age of 24 following a long battle with lupus.
  • The disease can devastate a child's growth and day-to-day life, and even shorten a child's life," said Joy Buie, PhD, MSCR, RN, Vice President of Research, Lupus Foundation of America.